Tags : Iptacopan

Novartis Presents Results of Iptacopan (LNP023) in P-ll Study for

Shots: The P-II study involves assessing the efficacy, safety and PK of Iptacopan (LNP023) in patients with C3G (Cohort A) and patients who have undergone a kidney transplant and have C3G recurrence (Cohort B), interim results presented at ASN 2020 Result: @12wks., reduction in proteinuria (49%) as measured by 24hrs. UPCR assessment; improvement in plasma […]Read More

Novartis’s Iptacopan (LNP023) Receives EMA’s Prime Designation for C3 Glomerulopathy

Shots: EMA has granted PRIME designation for iptacopan (LNP023) in C3 glomerulopathy (C3G). PRIME designation enhancing the development of medicine targeting unmet medical need. Results of P-II interim analysis for iptacopan in C3G will be presented at ASN 2020 Additionally, the company is investigating iptacopan in P-III study in PNH patients with residual anemia despite […]Read More